AIM: To evaluate the utility of a multigene real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay to detect circulating tumor cells in peripheral blood specimens of breast cancer patients during or after treatment. METHOD: Using this assay, peripheral blood samples were analyzed for expression levels of mammaglobin and three complementary transcribed breast cancer-specific genes: B305D, gamma-aminobutyrate type A receptor pi subunit (GABA pi; GABRP), and B726P. We examined 172 blood specimens from 82 breast cancer patients during or after therapy for the presence of circulating tumor cells using the multigene real-time RT-PCR assay. RESULTS: In 63.4% of the blood samples, a positive signal for mammaglobin and/or three breast cancer-associated gene transcripts was detected. Of breast cancer patients, 75.6% had at least one positive blood sample. Blood specimens from 51 of 53 healthy female volunteers tested negative in the assay whereas two samples had a low expression signal. In addition, three patients were monitored for more than a year during their adjuvant therapy treatment. CONCLUSION: This assay could be a valuable tool for monitoring breast cancer patients during and after therapy.
AIM: To evaluate the utility of a multigene real-time reverse transcriptase polymerase chain reaction (RT-PCR) assay to detect circulating tumor cells in peripheral blood specimens of breast cancerpatients during or after treatment. METHOD: Using this assay, peripheral blood samples were analyzed for expression levels of mammaglobin and three complementary transcribed breast cancer-specific genes: B305D, gamma-aminobutyrate type A receptor pi subunit (GABA pi; GABRP), and B726P. We examined 172 blood specimens from 82 breast cancerpatients during or after therapy for the presence of circulating tumor cells using the multigene real-time RT-PCR assay. RESULTS: In 63.4% of the blood samples, a positive signal for mammaglobin and/or three breast cancer-associated gene transcripts was detected. Of breast cancerpatients, 75.6% had at least one positive blood sample. Blood specimens from 51 of 53 healthy female volunteers tested negative in the assay whereas two samples had a low expression signal. In addition, three patients were monitored for more than a year during their adjuvant therapy treatment. CONCLUSION: This assay could be a valuable tool for monitoring breast cancerpatients during and after therapy.
Authors: J Klug; H M Beier; A Bernard; B S Chilton; T P Fleming; R I Lehrer; L Miele; N Pattabiraman; G Singh Journal: Ann N Y Acad Sci Date: 2000 Impact factor: 5.691
Authors: R L Houghton; D C Dillon; D A Molesh; B K Zehentner; J Xu; J Jiang; C Schmidt; A Frudakis; E Repasky; A Maltez Filho; M Nolasco; R Badaro; X Zhang; P C Roche; D H Persing; S G Reed Journal: Mol Diagn Date: 2001-06
Authors: P de Cremoux; J M Extra; M G Denis; J Y Pierga; E Bourstyn; C Nos; K B Clough; E Boudou; E C Martin; A Müller; P Pouillart; H Magdelénat Journal: Clin Cancer Res Date: 2000-08 Impact factor: 12.531
Authors: Yuqiu Jiang; Susan L Harlocker; David A Molesh; David C Dillon; John A Stolk; Raymond L Houghton; Elizabeth A Repasky; Roberto Badaro; Steven G Reed; Jiangchun Xu Journal: Oncogene Date: 2002-03-28 Impact factor: 9.867
Authors: D Jäger; E Stockert; A O Güre; M J Scanlan; J Karbach; E Jäger; A Knuth; L J Old; Y T Chen Journal: Cancer Res Date: 2001-03-01 Impact factor: 12.701
Authors: Barbara K Zehentner; David H Persing; Amadou Deme; Papa Toure; Stephen E Hawes; Lisa Brooks; Qinghua Feng; Dawn C Hayes; Cathy W Critichlow; Raymond L Houghton; Nancy B Kiviat Journal: Clin Chem Date: 2004-09-16 Impact factor: 8.327
Authors: María José Serrano Fernádez; Juan Carlos Alvarez Merino; Iñigo Martínez Zubiaurre; Ana Fernández García; Pedro Sánchez Rovira; José Antonio Lorente Acosta Journal: Clin Transl Oncol Date: 2009-10 Impact factor: 3.405
Authors: Michael P Raynor; Sally-Anne Stephenson; Kenneth B Pittman; David C A Walsh; Michael A Henderson; Alexander Dobrovic Journal: J Hematol Oncol Date: 2009-06-05 Impact factor: 17.388